In this study, the anti-anginal drug ranolazine is found to sensitize BRAF inhibitor-resistant melanoma to targeted therapy and immunotherapy by rewiring fatty acid oxidation and the methionine salvage pathway.
- Marta Redondo-Muñoz
- Francisco Javier Rodriguez-Baena
- Imanol Arozarena